Zyversa receives Nasdaq delisting notice for low bid price; will appeal

ZyVersa Therapeutics, Inc.

Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.
Ineligible for cure period due to two reverse stock splits in past two years (1:35 Dec 2023, 1:10 Apr 2024).
Unless appeal requested by June 3, 2025, securities face delisting on June 5, 2025.
Company intends to appeal and request hearing, which will stay delisting pending panel decision.
No assurance of regaining compliance with continued listing requirements.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.